Private Equity
Editas Medicine has hired Katrine S. Bosley as CEO. Previously, Bosley worked at Avila Therapeutics where she served as CEO. Based in Cambridge, Mass., Editas Medicine is a transformative genome editing firm. It is backed by Flagship Ventures, Polaris Partners, Third Rock Ventures and Partners Innovation Fund.
4 min read · 24 June 2014
Intel Corp. said Monday that it has added Aneel Bhusri to its board of directors. Bhusri is the co-founder and CEO of Workday. He is also a partner at Greylock.
2 min read · 23 June 2014
Invincea said Monday that it has named Norm Laudermilch as its chief operating officer. Previously, Laudermilch worked at Verizon's Terremark Federal Group where he served as COO. Based in Fairfax, Virginia, Invincea is a provider of cyber security solutions. Its backers include Aeris Capital, Dell Ventures, Grotech Ventures, Harbert Ventures and New Atlantic Ventures.
3 min read · 23 June 2014
Invincea said Monday that it has named Norm Laudermilch as its chief operating officer. Previously, Laudermilch worked at Verizon's Terremark Federal Group where he served as COO. Based in Fairfax, Virginia, Invincea is a provider of cyber security solutions. Its backers include Aeris Capital, Dell Ventures, Grotech Ventures, Harbert Ventures and New Atlantic Ventures.
3 min read · 23 June 2014
Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has added Jay Shepard and William D. Waddill to its board of directors. Shepard is an executive partner at Sofinnova Ventures while Waddill is the senior vice president and chief financial officer at Calithera Biosciences. Sorbent's backers include CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.
4 min read · 19 June 2014
Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has added Jay Shepard and William D. Waddill to its board of directors. Shepard is an executive partner at Sofinnova Ventures while Waddill is the senior vice president and chief financial officer at Calithera Biosciences. Sorbent's backers include CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.
4 min read · 19 June 2014
AgilOne has appointed Ted Farrell as chief technology officer and Dan Moore as vice president of customer success. Previously, Farrell worked at Badgeville where he served as chief technology officer while Moore worked at RightScale. Based in Mountain View, Calif., AgilOne is a cloud-based predictive marketing platform. Its backers include Tenaya Capital. Next World Capital, Four Rivers Group, Sequoia Capital and Mayfield Fund.
3 min read · 19 June 2014
AgilOne has appointed Ted Farrell as chief technology officer and Dan Moore as vice president of customer success. Previously, Farrell worked at Badgeville where he served as chief technology officer while Moore worked at RightScale. Based in Mountain View, Calif., AgilOne is a cloud-based predictive marketing platform. Its backers include Tenaya Capital. Next World Capital, Four Rivers Group, Sequoia Capital and Mayfield Fund.
3 min read · 19 June 2014
Thrasos Therapeutics Inc has hired Donald Notman as senior vice president and CFO. Previously, Notman worked at Leerink Partners as managing director and head of private capital markets. Based in Montréal, Thrasos is a biotherapeutics company focused on delivering new solutions for treating kidney disease. Update: In 2012, the company raised $35 million in a round led by SR One and with the participation of GSK Canada Life Sciences Innovation Fund, SW Co, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.
3 min read · 19 June 2014
Thrasos Therapeutics Inc has hired Donald Notman as senior vice president and CFO. Previously, Notman worked at Leerink Partners as managing director and head of private capital markets. Based in Montréal, Thrasos is a biotherapeutics company focused on delivering new solutions for treating kidney disease. Update: In 2012, the company raised $35 million in a round led by SR One and with the participation of GSK Canada Life Sciences Innovation Fund, SW Co, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.
3 min read · 19 June 2014
